Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 414

1.

Multicenter study of zoledronic acid administration in non-small-cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017.

Nakahara Y, Hosomi Y, Shibuya M, Mitsufuji H, Katagiri M, Naoki K, Soejima K, Nogami N, Nagase S, Nishikawa M, Minato K, Takiguchi Y, Seki N, Yamada K, Seto T, Okamoto H.

Mol Clin Oncol. 2019 Oct;11(4):349-353. doi: 10.3892/mco.2019.1903. Epub 2019 Jul 23.

2.

Resveratrol Targets Urokinase-Type Plasminogen Activator Receptor Expression to Overcome Cetuximab-Resistance in Oral Squamous Cell Carcinoma.

Uzawa K, Amelio AL, Kasamatsu A, Saito T, Kita A, Fukamachi M, Sawai Y, Toeda Y, Eizuka K, Hayashi F, Kato-Kase I, Sunohara M, Iyoda M, Koike K, Nakashima D, Ogawara K, Endo-Sakamoto Y, Shiiba M, Takiguchi Y, Yamauchi M, Tanzawa H.

Sci Rep. 2019 Aug 21;9(1):12179. doi: 10.1038/s41598-019-48717-w.

3.

Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia.

Ogura T, Takigawa N, Tomii K, Kishi K, Inoue Y, Ichihara E, Homma S, Takahashi K, Akamatsu H, Ikeda S, Inase N, Iwasawa T, Ohe Y, Ohta H, Onishi H, Okamoto I, Ogawa K, Kasahara K, Karata H, Kishimoto T, Kitamura Y, Gemma A, Kenmotsu H, Sakashita H, Sakamoto S, Sekine K, Takiguchi Y, Tada Y, Toyooka S, Nakayama Y, Nishioka Y, Hagiwara K, Hanibuchi M, Fukuoka J, Minegishi Y, Yanagihara T, Yamamoto N, Yamamoto H, Gaga M, Fong KM, Powell CA, Kiura K; DLD/TO Assemblies of JRS.

Respir Investig. 2019 Jul 31. pii: S2212-5345(18)30312-5. doi: 10.1016/j.resinv.2019.06.001. [Epub ahead of print] Review.

PMID:
31377122
4.

Simultaneous chylous ascites and chylothorax during ramucirumab plus docetaxel chemotherapy in a patient with non-small lung cell cancer.

Arai M, Maruta S, Fan MM, Imai C, Tawada A, Takiguchi Y.

Int Cancer Conf J. 2019 Feb 25;8(3):114-117. doi: 10.1007/s13691-019-00366-6. eCollection 2019 Jul.

PMID:
31218186
5.

Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202).

Miyanaga A, Kubota K, Hosomi Y, Okuma Y, Minato K, Fujimoto S, Okamoto H, Satouchi M, Isobe H, Aono H, Takiguchi Y, Gemma A; Tokyo Cooperative Oncology Group.

Jpn J Clin Oncol. 2019 May 9. pii: hyz064. doi: 10.1093/jjco/hyz064. [Epub ahead of print]

PMID:
31070750
6.

AMPK activation induced in pemetrexed-treated cells is associated with development of drug resistance independently of target enzyme expression.

Qin Y, Sekine I, Hanazono M, Morinaga T, Fan M, Takiguchi Y, Tada Y, Shingyoji M, Yamaguchi N, Tagawa M.

Mol Oncol. 2019 Jun;13(6):1419-1432. doi: 10.1002/1878-0261.12496. Epub 2019 May 15.

7.

Corrigendum to "Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan" [Lung Cancer, 129 (March) (2019) 55-62].

Watanabe S, Yoshioka H, Sakai H, Hotta K, Takenoyama M, Yamada K, Sugawara S, Takiguchi Y, Hosomi Y, Tomii K, Niho S, Yamamoto N, Nishio M, Ohe Y, Kato T, Takahashi T, Kamada A, Suzukawa K, Omori Y, Enatsu S, Nakagawa K, Tamura T.

Lung Cancer. 2019 Jun;132:157-158. doi: 10.1016/j.lungcan.2019.04.010. Epub 2019 Apr 20. No abstract available.

8.

A Repeated Biopsy by EBUS-TBNA Contributed to the Selection of an Appropriate Therapeutic Regimen for a Lung Cancer Patient.

Naito J, Toyoda T, Nakajima T, Fujiwara T, Iwasawa S, Suzuki H, Takiguchi Y, Yoshino I.

J Bronchology Interv Pulmonol. 2019 Apr;26(2):129-131. doi: 10.1097/LBR.0000000000000571.

PMID:
30913043
9.

Single-Shot Optical Anisotropy Imaging with Quantitative Polarization Interference Microscopy.

Ge B, Zhou R, Takiguchi Y, Yaqoob Z, So PTC.

Laser Photon Rev. 2018 Aug;12(8). pii: 1800070. doi: 10.1002/lpor.201800070. Epub 2018 Jun 10.

10.

Short term outcomes of helical tomotherapy during concurrent chemoradiotherapy for advanced cervical cancer.

Mabuchi Y, Takiguchi Y, Yahata T, Mizoguchi M, Sasaki N, Ota N, Minami S, Ino K.

Mol Clin Oncol. 2019 Mar;10(3):382-386. doi: 10.3892/mco.2019.1806. Epub 2019 Jan 23.

11.

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan.

Watanabe S, Yoshioka H, Sakai H, Hotta K, Takenoyama M, Yamada K, Sugawara S, Takiguchi Y, Hosomi Y, Tomii K, Niho S, Yamamoto N, Nishio M, Ohe Y, Kato T, Takahashi T, Kamada A, Suzukawa K, Omori Y, Enatsu S, Nakagawa K, Tamura T.

Lung Cancer. 2019 Mar;129:55-62. doi: 10.1016/j.lungcan.2019.01.005. Epub 2019 Jan 16. Erratum in: Lung Cancer. 2019 Jun;132:157-158.

12.

Growth suppression of human oral cancer cells by candidate agents for cetuximab-side effects.

Uzawa K, Kasamatsu A, Saito T, Kita A, Sawai Y, Toeda Y, Koike K, Nakashima D, Endo Y, Shiiba M, Takiguchi Y, Tanzawa H.

Exp Cell Res. 2019 Mar 15;376(2):210-220. doi: 10.1016/j.yexcr.2019.01.016. Epub 2019 Jan 25.

PMID:
30690028
13.

Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.

Hayashi H, Kurata T, Takiguchi Y, Arai M, Takeda K, Akiyoshi K, Matsumoto K, Onoe T, Mukai H, Matsubara N, Minami H, Toyoda M, Onozawa Y, Ono A, Fujita Y, Sakai K, Koh Y, Takeuchi A, Ohashi Y, Nishio K, Nakagawa K.

J Clin Oncol. 2019 Mar 1;37(7):570-579. doi: 10.1200/JCO.18.00771. Epub 2019 Jan 17.

PMID:
30653423
14.

Long-Term Prognosis of Patients with Obscure Gastrointestinal Bleeding: A Retrospective Cohort Study.

Arai M, Matsumura T, Ohta Y, Kiyono S, Hayashi M, Taida T, Saito K, Okimoto K, Maruoka D, Nakagawa T, Katsuno T, Kato N, Takiguchi Y.

Digestion. 2019;100(1):37-44. doi: 10.1159/000493854. Epub 2019 Jan 11.

PMID:
30636251
15.

Removal of surface-normal spot beam from on-chip 2D beam pattern projecting lasers.

Hirose K, Takiguchi Y, Sugiyama T, Nomoto Y, Uenoyama S, Kurosaka Y.

Opt Express. 2018 Nov 12;26(23):29854-29866. doi: 10.1364/OE.26.029854.

PMID:
30469944
16.

[Dawn of Cancer Clinical Sequencing in Chiba University Hospital].

Kano M, Miyauchi H, Matsushita K, Murakami K, Toyozumi T, Hayano K, Otsuka R, Takahashi M, Sekino N, Shiraishi T, Arai M, Takiguchi Y, Matsubara H.

Gan To Kagaku Ryoho. 2018 Oct;45(10):1463-1465. Japanese.

PMID:
30382046
17.

Use of modified U1 small nuclear RNA for rescue from exon 7 skipping caused by 5'-splice site mutation of human cathepsin A gene.

Yamazaki N, Kanazawa K, Kimura M, Ike H, Shinomiya M, Tanaka S, Shinohara Y, Minakawa N, Itoh K, Takiguchi Y.

Gene. 2018 Nov 30;677:41-48. doi: 10.1016/j.gene.2018.07.030. Epub 2018 Jul 24.

PMID:
30010039
18.

Intracardiac Tumors With Extracardiac Extension Diagnosed by Endoscopic Ultrasound With Bronchoscope-Guided Fine-Needle Aspiration.

Inage T, Nakajima T, Sata Y, Fujiwara T, Iwasawa S, Takiguchi Y, Nakatani Y, Yoshino I.

Ann Thorac Surg. 2019 Jan;107(1):e5-e7. doi: 10.1016/j.athoracsur.2018.05.046. Epub 2018 Jun 15.

PMID:
29908982
19.

Rapid growth of pulmonary artery after intrapulmonary artery septation.

Agematsu K, Okamura T, Takiguchi Y, Yoneyama F, Harada Y.

Asian Cardiovasc Thorac Ann. 2018 Jul;26(6):479-481. doi: 10.1177/0218492318782821. Epub 2018 Jun 7.

PMID:
29877716
20.

A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study Protocol.

Kogure Y, Saka H, Takiguchi Y, Atagi S, Kurata T, Ebi N, Inoue A, Kubota K, Takenoyama M, Seto T, Kada A, Yamanaka T, Ando M, Yamamoto N, Gemma A, Ichinose Y.

Clin Lung Cancer. 2018 Sep;19(5):e711-e715. doi: 10.1016/j.cllc.2018.05.005. Epub 2018 May 19.

PMID:
29861395
21.

Principle of beam generation in on-chip 2D beam pattern projecting lasers.

Takiguchi Y, Hirose K, Sugiyama T, Nomoto Y, Uenoyama S, Kurosaka Y.

Opt Express. 2018 Apr 16;26(8):10787-10800. doi: 10.1364/OE.26.010787.

PMID:
29716010
22.

Repression of Nitrogen Starvation Responses by Members of the Arabidopsis GARP-Type Transcription Factor NIGT1/HRS1 Subfamily.

Kiba T, Inaba J, Kudo T, Ueda N, Konishi M, Mitsuda N, Takiguchi Y, Kondou Y, Yoshizumi T, Ohme-Takagi M, Matsui M, Yano K, Yanagisawa S, Sakakibara H.

Plant Cell. 2018 Apr;30(4):925-945. doi: 10.1105/tpc.17.00810. Epub 2018 Apr 5.

23.

Pulmonary vein obstruction after primary sutureless pericardial repair of a total anomalous pulmonary venous connection.

Agematsu K, Okamura T, Takiguchi Y, Harada Y.

Interact Cardiovasc Thorac Surg. 2018 Oct 1;27(4):624-625. doi: 10.1093/icvts/ivy096.

PMID:
29618066
24.

Cardiac perforation 6 years following the implantation of an Amplatzer septal occluder.

Agematsu K, Okamura T, Takiguchi Y, Harada Y.

J Card Surg. 2018 Feb;33(2):105-106. doi: 10.1111/jocs.13540. Epub 2018 Feb 19. No abstract available.

PMID:
29460301
25.

Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site.

Kodaira M, Yonemori K, Shimoi T, Yoshida A, Yoshida M, Kitano A, Shimomura A, Yunokawa M, Shimizu C, Takiguchi Y, Fujiwara Y, Tamura K.

BMC Cancer. 2018 Feb 13;18(1):176. doi: 10.1186/s12885-018-4092-4.

26.

Inhibition of Gli leads to antitumor growth and enhancement of cisplatin-induced cytotoxicity in large cell neuroendocrine carcinoma of the lung.

Ishiwata T, Iwasawa S, Ebata T, Fan M, Tada Y, Tatsumi K, Takiguchi Y.

Oncol Rep. 2018 Mar;39(3):1148-1154. doi: 10.3892/or.2018.6183. Epub 2018 Jan 3.

PMID:
29328464
27.

Augmented expression of cardiac ankyrin repeat protein is induced by pemetrexed and a possible marker for the pemetrexed resistance in mesothelioma cells.

Qin Y, Sekine I, Fan M, Takiguchi Y, Tada Y, Shingyoji M, Hanazono M, Yamaguchi N, Tagawa M.

Cancer Cell Int. 2017 Dec 11;17:120. doi: 10.1186/s12935-017-0493-8. eCollection 2017.

28.

Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04).

Katakami N, Uchino J, Yokoyama T, Naito T, Kondo M, Yamada K, Kitajima H, Yoshimori K, Sato K, Saito H, Aoe K, Tsuji T, Takiguchi Y, Takayama K, Komura N, Takiguchi T, Eguchi K.

Cancer. 2018 Feb 1;124(3):606-616. doi: 10.1002/cncr.31128. Epub 2017 Dec 4.

29.

Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP).

Ishiwata T, Ebata T, Iwasawa S, Matsushima J, Ota S, Nakatani Y, Tsushima K, Tada Y, Tatsumi K, Takiguchi Y.

Intern Med. 2017 Sep 1;56(17):2311-2315. doi: 10.2169/internalmedicine.8271-16. Epub 2017 Aug 10.

30.

Large-scale comprehensive immunohistochemical biomarker analyses in esophageal squamous cell carcinoma.

Hatogai K, Fujii S, Kojima T, Daiko H, Nomura S, Doi T, Kitano S, Ohtsu A, Takiguchi Y, Yoshino T, Ochiai A.

J Cancer Res Clin Oncol. 2017 Nov;143(11):2351-2361. doi: 10.1007/s00432-017-2482-7. Epub 2017 Jul 29.

PMID:
28756492
31.

Pirfenidone may revert the epithelial-to-mesenchymal transition in human lung adenocarcinoma.

Kurimoto R, Ebata T, Iwasawa S, Ishiwata T, Tada Y, Tatsumi K, Takiguchi Y.

Oncol Lett. 2017 Jul;14(1):944-950. doi: 10.3892/ol.2017.6188. Epub 2017 May 17.

32.

Pulmonary Nocardiosis: A Clinical Analysis of 30 Cases.

Takiguchi Y, Ishizaki S, Kobayashi T, Sato S, Hashimoto Y, Suruga Y, Akiba Y.

Intern Med. 2017;56(12):1485-1490. doi: 10.2169/internalmedicine.56.8163. Epub 2017 Jun 15.

33.

Amrubicin Monotherapy for Patients with Platinum-Pretreated Non-Gastrointestinal Non-Pancreatic Extrapulmonary Neuroendocrine Carcinoma.

Ebata T, Shimoi T, Ishiwata T, Iwasawa S, Bun S, Yunokawa M, Yonemori K, Takiguchi Y, Tamura K.

Oncology. 2017;93(3):177-182. doi: 10.1159/000475669. Epub 2017 May 19.

PMID:
28521313
34.

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.

Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T.

Lancet. 2017 Jul 1;390(10089):29-39. doi: 10.1016/S0140-6736(17)30565-2. Epub 2017 May 10.

PMID:
28501140
35.

[Surgical Treatment of Left Main Trunk Coronary Artery Aneurysm with Asymptomatic Myocardial Ischemia;Report of a Case].

Okugi S, Saito H, Umeda E, Takiguchi Y.

Kyobu Geka. 2017 May;70(5):381-384. Japanese.

PMID:
28496086
36.

Assessment of hyperacusis with a newly produced Japanese version of the Khalfa hyperacusis questionnaire.

Oishi N, Yamada H, Kanzaki S, Kurita A, Takiguchi Y, Yuge I, Asama Y, Masuda M, Ogawa K.

Acta Otolaryngol. 2017 Sep;137(9):957-961. doi: 10.1080/00016489.2017.1306654. Epub 2017 Apr 10.

PMID:
28394666
37.

Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity.

Shiiba M, Yamagami H, Yamamoto A, Minakawa Y, Okamoto A, Kasamatsu A, Sakamoto Y, Uzawa K, Takiguchi Y, Tanzawa H.

Oncol Rep. 2017 Apr;37(4):2025-2032. doi: 10.3892/or.2017.5480. Epub 2017 Mar 1.

PMID:
28259989
38.

Potential Activity of Amrubicin as a Salvage Therapy for Merkel Cell Carcinoma.

Sakaida E, Ebata T, Iwasawa S, Kurimoto R, Yonemori S, Ota S, Nakatani Y, Sekine I, Takiguchi Y.

Intern Med. 2017;56(5):567-570. doi: 10.2169/internalmedicine.56.7675. Epub 2017 Mar 1.

39.

A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016).

Miura S, Maemondo M, Iwashima A, Harada T, Sugawara S, Kobayashi K, Inoue A, Nakagawa T, Takiguchi Y, Watanabe H, Ishida T, Terada M, Kagamu H, Gemma A, Yoshizawa H.

Invest New Drugs. 2017 Apr;35(2):227-234. doi: 10.1007/s10637-017-0436-1. Epub 2017 Feb 1.

PMID:
28150074
40.

Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma.

Hatogai K, Fujii S, Kojima T, Daiko H, Doi T, Ohtsu A, Ochiai A, Takiguchi Y, Yoshino T.

BMC Cancer. 2017 Jan 9;17(1):36. doi: 10.1186/s12885-016-3041-3.

41.

Prognosis of Good syndrome: mortality and morbidity of thymoma associated immunodeficiency in perspective.

Jansen A, van Deuren M, Miller J, Litzman J, de Gracia J, Sáenz-Cuesta M, Szaflarska A, Martelius T, Takiguchi Y, Patel S, Misbah S, Simon A; Good syndrome Study Group.

Clin Immunol. 2016 Oct;171:12-17. doi: 10.1016/j.clim.2016.07.025. Epub 2016 Aug 4.

42.

Phase-modulating lasers toward on-chip integration.

Kurosaka Y, Hirose K, Sugiyama T, Takiguchi Y, Nomoto Y.

Sci Rep. 2016 Jul 26;6:30138. doi: 10.1038/srep30138.

43.

Identification of Plants That Inhibit Lipid Droplet Formation in Liver Cells: Rubus suavissimus Leaf Extract Protects Mice from High-Fat Diet-Induced Fatty Liver by Directly Affecting Liver Cells.

Takahashi T, Sugawara W, Takiguchi Y, Takizawa K, Nakabayashi A, Nakamura M, Nagano-Ito M, Ichikawa S.

Evid Based Complement Alternat Med. 2016;2016:4282758. doi: 10.1155/2016/4282758. Epub 2016 Jun 26.

44.

A Dilemma on Re-biopsy in the Era of Precision Cancer Therapy.

Takiguchi Y.

Intern Med. 2016;55(13):1683-4. doi: 10.2169/internalmedicine.55.6567. Epub 2016 Jul 1. No abstract available.

45.

Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma.

Hatogai K, Kitano S, Fujii S, Kojima T, Daiko H, Nomura S, Yoshino T, Ohtsu A, Takiguchi Y, Doi T, Ochiai A.

Oncotarget. 2016 Jul 26;7(30):47252-47264. doi: 10.18632/oncotarget.10055.

46.

Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015.

Kozuki T, Nogami N, Kitajima H, Iwasawa S, Sakaida E, Takiguchi Y, Ikeda S, Yoshida M, Kato T, Miyamoto S, Sakamaki K, Shinkai T, Watanabe K.

BMC Cancer. 2016 May 12;16:306. doi: 10.1186/s12885-016-2338-6.

47.

Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.

Hatogai K, Fujii S, Kojima T, Daiko H, Kadota T, Fujita T, Yoshino T, Doi T, Takiguchi Y, Ohtsu A.

J Surg Oncol. 2016 Mar;113(4):390-6. doi: 10.1002/jso.24151. Epub 2016 Jan 12.

PMID:
27100024
48.

An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol.

Tada Y, Hiroshima K, Shimada H, Shingyoji M, Suzuki T, Umezawa H, Sekine I, Takiguchi Y, Tatsumi K, Tagawa M.

Springerplus. 2016 Feb 27;5:195. doi: 10.1186/s40064-016-1893-2. eCollection 2016.

49.

Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial.

Takayama K, Katakami N, Yokoyama T, Atagi S, Yoshimori K, Kagamu H, Saito H, Takiguchi Y, Aoe K, Koyama A, Komura N, Eguchi K.

Support Care Cancer. 2016 Aug;24(8):3495-505. doi: 10.1007/s00520-016-3144-z. Epub 2016 Mar 23.

50.

Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients-Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study.

Takayama K, Atagi S, Imamura F, Tanaka H, Minato K, Harada T, Katakami N, Yokoyama T, Yoshimori K, Takiguchi Y, Hataji O, Takeda Y, Aoe K, Kim YH, Yokota S, Tabeta H, Tomii K, Ohashi Y, Eguchi K, Watanabe K.

Support Care Cancer. 2016 Aug;24(8):3473-80. doi: 10.1007/s00520-016-3156-8. Epub 2016 Mar 22.

Supplemental Content

Loading ...
Support Center